Dr. Pal on an Enrolling Clinical Trial for Patients With GU Cancers

Sumanta Kumar Pal, MD
Published: Monday, Jun 04, 2018



Sumanta Kumar Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses an enrolling trial for patients with genitourinary (GU) cancers.

Physicians have seen atezolizumab (Tecentriq) work across a spectrum of cancer types, including impressive frontline data in the IMmotion150 trial in advanced renal cell carcinoma (RCC). There are a lot of data for atezolizumab, specifically in the context of bladder cancer, says Pal.

Neeraj Agarwal, MD, from the Huntsman Cancer Institute, and Sumanta Kumar Pal, MD, from City of Hope, are chairing a trial that will look at cabozantinib (Cabometyx), a very potent multikinase VEGF inhibitor, alongside atezolizumab in a phase 1b trial in patients with locally advanced or metastatic urothelial carcinoma or RCC (NCT03170960).

There are multiple cohorts, says Pal. There is a cohort for patients in the frontline setting with untreated metastatic RCC. There are also multiple cohorts in bladder cancer for cisplatin- and carboplatin-pretreated patients who are cisplatin ineligible. Another cohort will examine patients who may be eligible for cisplatin but choose not to receive it, concludes Pal.
 


Sumanta Kumar Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses an enrolling trial for patients with genitourinary (GU) cancers.

Physicians have seen atezolizumab (Tecentriq) work across a spectrum of cancer types, including impressive frontline data in the IMmotion150 trial in advanced renal cell carcinoma (RCC). There are a lot of data for atezolizumab, specifically in the context of bladder cancer, says Pal.

Neeraj Agarwal, MD, from the Huntsman Cancer Institute, and Sumanta Kumar Pal, MD, from City of Hope, are chairing a trial that will look at cabozantinib (Cabometyx), a very potent multikinase VEGF inhibitor, alongside atezolizumab in a phase 1b trial in patients with locally advanced or metastatic urothelial carcinoma or RCC (NCT03170960).

There are multiple cohorts, says Pal. There is a cohort for patients in the frontline setting with untreated metastatic RCC. There are also multiple cohorts in bladder cancer for cisplatin- and carboplatin-pretreated patients who are cisplatin ineligible. Another cohort will examine patients who may be eligible for cisplatin but choose not to receive it, concludes Pal.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x